Related Experiment Video
Updated: Aug 4, 2026
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Tumefactive Demyelinating Lesions in a Patient with Multiple Sclerosis Developed two Days after the Injection of
1MS Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran.
Background:
Rituximab has been increasingly prescribed in the treatment of multiple sclerosis (MS) over recent years. Tumefactive demyelinating lesions can occur at the onset or over the course of MS. Another major cause of these lesions is the side effects of drugs such as natalizumab or fingolimod. This study is a case report of a young MS patient who suffered from tumefactive lesions following the injection of rituximab.
Case Presentation:
The patient was an 18-year-old man with MS who developed double vision, imbalance, and quadriparesis symptoms followed by a decrease in his consciousness two days after administration of rituximab. Tumefactive lesions were observed in the patient's brain magnetic resonance imaging (MRI).
Conclusion:
Rituximab should be considered as a potential cause of tumefactive demyelinating lesions in patients with MS.
More Related Videos
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
09:41Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
Related Concept Videos
01:26Rocky Mountain Spotted Fever
01:19Multiple Sclerosis l: Introduction